Gilead's Biktarvy build its case for long-term use with 4-year data showing lasting HIV suppression
Gilead Sciences’ daily pill Biktarvy has been one of biopharma’s great success stories, riding its market leading HIV efficacy data to one of the best launches on record. Now, settling into its role as an established brand, Biktarvy is sporting four-year data that will look to keep patients on board even longer.
After four years of treatment with Biktarvy, 98% of HIV patients who had never received a prior antiviral posted viral loads at “undetectable” levels with no new resistance to the drug, according to data from open-label expansions of two Phase III studies presented Saturday at the virtual Conference on Retroviruses and Opportunistic Infections (CROI).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.